Veronese S - Search Results

1

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.

Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M. Valtorta E, et al. Among authors: veronese s. Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9. Mod Pathol. 2015. PMID: 26449765 Free article. Clinical Trial.

2

[Automatic system for the determination of nuclear antigens. Its application in carcinoma of the breast].

Gambacorta M, Veronese S, Negri E. Gambacorta M, et al. Among authors: veronese s. Pathologica. 1992 Nov-Dec;84(1094):33-7. Pathologica. 1992. PMID: 1300531 Italian. No abstract available.

3

Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features.

Veronese SM, Gambacorta M. Veronese SM, et al. Am J Clin Pathol. 1991 Jan;95(1):30-4. doi: 10.1093/ajcp/95.1.30. Am J Clin Pathol. 1991. PMID: 1987749

4

In situ demonstration of tissue proliferative activity using anti-bromo-deoxyuridine monoclonal antibody.

Veronese S, Gambacorta M, Falini B. Veronese S, et al. J Clin Pathol. 1989 Aug;42(8):820-6. doi: 10.1136/jcp.42.8.820. J Clin Pathol. 1989. PMID: 2475528 Free PMC article.

5

Proliferation index as a prognostic marker in breast cancer.

Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P. Veronese SM, et al. Cancer. 1993 Jun 15;71(12):3926-31. doi: 10.1002/1097-0142(19930615)71:12<3926::aid-cncr2820711221>3.0.co;2-2. Cancer. 1993. PMID: 8508358

6

Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors.

Moroni M, Veronese S, Schiavo R, Carminati O, Sorensen BS, Gambacorta M, Siena S. Moroni M, et al. Among authors: veronese s. Clin Cancer Res. 2001 Sep;7(9):2770-5. Clin Cancer Res. 2001. PMID: 11555591

7

Absence of c-Kit and members of the epidermal growth factor receptor family in refractory germ cell cancer.

Moroni M, Schiavo R, Siena S, Veronese S. Moroni M, et al. Among authors: veronese s. Cancer. 2003 Jun 1;97(11):2926-7; author reply 2927-8. doi: 10.1002/cncr.11403. Cancer. 2003. PMID: 12767109 Free article. No abstract available.

8

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Moroni M, et al. Among authors: veronese s. Lancet Oncol. 2005 May;6(5):279-86. doi: 10.1016/S1470-2045(05)70102-9. Lancet Oncol. 2005. PMID: 15863375 Clinical Trial.

9

Treatment of metastatic neuroendocrine carcinomas based on WHO classification.

Artale S, Giannetta L, Cerea G, Maggioni D, Pedrazzoli P, Schiavetto I, Napolitano M, Veronese S, Bramerio E, Gambacorta M, Vanzulli A, Pisconti S, Pugliese R, Siena S. Artale S, et al. Among authors: veronese s. Anticancer Res. 2005 Nov-Dec;25(6C):4463-9. Anticancer Res. 2005. PMID: 16334127 Free article.

10

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Benvenuti S, et al. Among authors: veronese s. Cancer Res. 2007 Mar 15;67(6):2643-8. doi: 10.1158/0008-5472.CAN-06-4158. Cancer Res. 2007. PMID: 17363584

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

171 results

Search Page